- Home
- EDUC vs CURX Comparison
EDUC vs CURX Comparison
Compare EDUC & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDUC | CURX |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 12.4M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | EDUC | CURX |
|---|---|---|
| Price | $1.49 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.2K | ★ 100.4K |
| Earning Date | 05-19-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $34,191,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $0.26 |
| 52 Week High | $1.84 | $9.18 |
Technical Indicators
Market Signals| Indicator | EDUC | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 75.21 | 29.90 |
| Support Level | $1.25 | $0.26 |
| Resistance Level | $1.54 | $0.51 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 79.17 | 7.06 |
Price Performance
Historical ComparisonAbout EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.